MedTrace Logo

Appraisal of the Modified Cancer Cachexia Index in Locally Advanced Gastric Cancer Patients Undergoing Neoadjuvant Chemotherapy

NCT06689462 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2024-11-14

No results posted yet for this study

Summary

In this study, consecutive 600 patients with LAGC(cT2-4NanyM0) who underwent NACT between Jan. 2010 and Jun. 2022 were identified from two tertiary hospitals. The mCXI was constructed based on Random Forest model, calculated as (post-NACT L3 subcutaneous adipose tissue area \[SAT\])×(post-NACT serum albumin \[ALB\])/(post-NACT platelet count \[PLT\]). Patients were categorized into two subgroups: mCXI-low and mCXI-high. mCXI is associated with the overall prognosis in patients with locally advanced gastric cancer underwent neoadjuvant chemotherapy, is superior to traditional CXI, and may serve as a decision-making tool for guiding personalized postoperative adjuvant chemotherapy.

Conditions

  • Gastric Cancer
  • Neoadjuvant Chemotherapy
  • Computed Tomography
  • Random Forest Model

Sponsors & Collaborators

  • Fujian Medical University

    lead OTHER

Principal Investigators

  • Chang-Ming Huang, M.D. FACS · Fujian Medical University Union Hospital

Eligibility

Min Age
18 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-06-30
Completion
2024-07-13

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06689462 on ClinicalTrials.gov